Viral myocarditis is most frequently associated with infection by Coxsackievirus B3 (CVB3). Interferon (IFN)-β therapy has been studied and could reduce virally induced tissue damage and improve heart function.
Methods
In the present study we have investigated the role of translational suppression in the context of an IFN-α/β-mediated antiviral immune response to CVB3 infection. Specifically, we examined the effects of IFN-α/β treatment of CVB3-infected mouse embryonic fibroblast cells and splenocytes lacking eukaryotic initiation factor 4E binding protein-1 (4E-BP1), a suppressor of 5′-capped mRNA translation. Extending these in vitro studies, we examined the effects of CVB3 infection and IFN-β treatment in 4E-BP1-/- mice.
Results
Our data show that 4E-BP1-/- cells are more sensitive to the antiviral effects of IFN-α4 and IFN-β treatment than 4E-BP1+/+ cells when infected with CVB3. Similarly, 4E-BP1-/- mice are more sensitive to treatment with IFN-β, exhibiting lower viral titres in heart tissue than 4E-BP1+/+ mice during the course of infection. Additionally, we demonstrate that treatment with IFN-β reduces inflammatory infiltrates into the hearts of infected mice.
Conclusions
These data identify 4E-BP1 as a novel drug target to augment responsiveness to IFN-β therapy in CVB3-induced myocarditis.
EllisC.R., Di SalvoT.Myocarditis: basic and clinical aspects. Cardiol Rev2007; 15: 170–177.
4.
LiuP.P., MasonJ.W.Advances in the understanding of myocarditis. Circulation2001; 104: 1076–1082.
5.
KühlU., PauschingerM., SchwimmbeckP.L.Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation2003; 107: 2793–2798.
6.
BowlesN.E., NiJ., KearneyD.L., PauschingerM.Detection of viruses in myocardial tissues by polymerase chain reaction: evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol2003; 42: 466–472.
7.
KimK.S., HufnagelG., ChapmanN.M., TracyS.The group B coxsackieviruses and myocarditis. Rev Med Virol2001; 11: 355–368.
8.
TracyS., ChapmanN.M., McManusB.M., PallanschM.A., BeckM.A., CarstensJ.A molecular and serologic evaluation of enteroviral involvement in human myocarditis. J Mol Cell Cardiol1990; 22: 403–414.
9.
KühlU., PauschingerM., NoutsiasM.High prevalence of viral genomes and multiple viral infections in the myocardium of adults with ‘idiopathic’ left ventricular dysfunction. Circulation2005; 111: 887–893.
10.
KühlU., PauschingerM., SeebergB.Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation2005; 112: 1965–1970.
11.
StewartM.J., SmoakK., BlumM.A., SherryB.Basal and reovirus-induced beta interferon (IFN-β) and IFN-β-stimulated gene expression are cell type specific in the cardiac protective response. J Virol2005; 79: 2979–2987.
12.
ZurneyJ., HowardK.E., SherryB.Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses. J Virol2007; 81: 13668–13680.
13.
RichtsteigerR., Henke-GendoC., SchmidtkeM., HarsteG., HeimA.Quantitative multiplex real-time PCR for the sensitive detection of interferon β gene induction and viral suppression of interferon β expression. Cytokine2003; 24: 190–200.
14.
KerekatteV., KeiperB.D., BadorffC., CaiA., KnowltonK.U., RhoadsR.E.Cleavage of poly(A)-binding protein by coxsackievirus 2A protease in vitro and in vivo: another mechanism for host protein synthesis shutoff?J Virol1999; 73: 709–717.
15.
JoachimsM., Van BreugelP.C., LloydR.E.Cleavage of poly(A)-binding protein by enterovirus proteases concurrent with inhibition of translation in vitro. J Virol1999; 73: 718–727.
16.
SommergruberW., AhornH., KlumpH.2A proteinases of coxsackie- and rhinovirus cleave peptides derived from elF-4γ via a common recognition motif. Virology1994; 198: 741–745.
17.
LiebigH.D., ZieglerE., YanR.Purification of two picornaviral 2A proteinases: interaction with eIF-4γ and influence on in vitro translation. Biochemistry1993; 32: 7581–7588.
18.
LamphearB.J., YanR., YangF.Mapping the cleavage site in protein synthesis initiation factor eIF-4γ of the 2A proteases from human coxsackievirus and rhinovirus. J Biol Chem1993; 268: 19200–19203.
19.
EsfandiareiM., LuoH., YanagawaB.Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent. J Virol2004; 78: 4289–4298.
20.
CornellC.T., KiossesW.B., HarkinsS., WhittonJ.L.Inhibition of protein trafficking by coxsackievirus B3: Multiple viral proteins target a single organelle. J Virol2006; 80: 6637–6647.
21.
CornellC.T., KiossesW.B., HarkinsS., WhittonJ.L.Coxsackievirus B3 proteins directionally complement each other to downregulate surface major histocompatibility complex class I. J Virol2007; 81: 6785–6797.
22.
DoddD.A., GiddingsT.H.J., KirkegaardK.Poliovirus 3A protein limits interleukin-6 (IL-6), IL-8, and beta interferon secretion during viral infection. J Virol2001; 75: 8158–8165.
23.
KaurS., LalL., SassanoA.Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem2007; 282: 1757–1768.
24.
DeonarainR., CerulloD., FuseK., LiuP.P., FishE.N.Protective role for interferon-beta in coxsackievirus B3 infection. Circulation2004; 110: 3540–3543.
25.
WangY.X., Da CunhaV., VinceletteJ.Antiviral and myocyte protective effects of murine interferon-β and -α2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice. Am J Physiol Heart Circ Physiol2007; 293: H69–H76.
MatsumoriA., TomiokaN., KawaiC.Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J1988; 115: 1229–1232.
28.
BordenE.C., SenG.C., UzeG.Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov2007; 6: 975–990.
29.
ParmarS., PlataniasL.C.Interferons: Mechanisms of action and clinical applications. Curr Opin Oncol2003; 15: 431–439.
30.
LekmineF., SassanoA., UddinS.Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp Cell Res2004; 295: 173–182.
31.
LekmineF., UddinS., SassanoA.Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J Biol Chem2003; 278: 27772–27780.
32.
GuiducciC., GhirelliC., Marloie-ProvostM.A.PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J Exp Med2008; 205: 315–322.
33.
CaoW., ManicassamyS., TangH.Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol2008; 9: 1157–1164.
34.
SchmitzF., HeitA., DreherS.Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol2008; 38: 2981–2992.
35.
ColinaR., Costa-MattioliM., DowlingR.J.Translational control of the innate immune response through IRF-7. Nature2008; 452: 323–328.
HenkeA., HuberS., StelznerA., WhittonJ.L.The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J Virol1995; 69: 6720–6728.
38.
OpavskyM.A., PenningerJ., AitkenK.Susceptibility to myocarditis is dependent on the response of αβ T lymphocytes to coxsackieviral infection. Circ Res1999; 85: 551–558.
